Publication:
Is the subcutaneous allergen immunotherapy safe enough as a treatment modality?

dc.contributor.authorEdiger, Dane
dc.contributor.authorYılmaz, Dilber
dc.contributor.authorCoşkun, Funda
dc.contributor.authorGözü, Oktay
dc.contributor.buuauthorEDİGER, DANE
dc.contributor.buuauthorYılmaz, Dilber
dc.contributor.buuauthorCOŞKUN, NECMİYE FUNDA
dc.contributor.buuauthorGözü, Oktay
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentGöğüs Hastalıkları Ana Bilim Dalı
dc.contributor.departmentGöğüs Hastalıkları Ana Bilim Dalı
dc.contributor.departmentAlerji Bilim Dalı
dc.contributor.orcid0000-0002-2954-4293
dc.contributor.orcid0000-0003-3604-8826
dc.contributor.researcheridAAD-1271-2019
dc.contributor.researcheridAAE-9142-2019
dc.contributor.researcheridEGU-1690-2022
dc.contributor.researcheridEWV-3115-2022
dc.date.accessioned2024-10-01T08:53:06Z
dc.date.available2024-10-01T08:53:06Z
dc.date.issued2010-01-01
dc.description.abstractObjective: Allergen immunotherapy has been proven to be effective and potentially curative therapy in allergic respiratory diseases and in venom allergy. But occurance of adverse systemic reactions due to specific allergen immunotherapy (SIT) remains still major problem. In this study we aimed to assess the adverse reactions of SIT which has been given to patients diagnosed as allergic asthma and/or rhinitis.Materials and Methods: The 58 patients (37 female/21 male) followed up at Allergy Outpatient and received SIT were included to the study. Local or systemic reactions that occured during total 2939 injections were analyzed.Results: Total 2939 injections with standardized allergen extracts were administered to patients diagnosed as allergic asthma (n= 9), allergic rhinitis (n= 6), allergic asthma and allergic rhinitis (n= 43). Total 39 (1.3%) reactions were observed in 15 (25.8%) patients. Among these reactions 20 ones were local and 19 ones were systemic reactions. Among reactions 15 (75%) of local and 14 (73.7%) of systemic were occurred during build-up phase; 5 (25%) of local and 5 (26.3%) of systemic were occurred during maintenance phase (p< 0.05). According to allergen type while among systemic reactions 13 (68.4%) occured by polen extracts and 6 (31.6%) by mite extracts, among local reactions 15 (75%) occurred by polen extracts and 5 (25%) by mite extracts. (p< 0.05). These systemic reactions were urticaria, itching of body, flushing and feeling of fever, dyspnea and vertigo/headache. Reactions due to grass polen allergen occurred during season were two systemic and one local reaction.Conclusion: We believe that spesific immunotherapy is safe when used with strict safety protocols and administered by staff specialized in allergy. It is needed to have more researches to determine the factors predisposing the adverse reactions to SIT.
dc.identifier.endpage156
dc.identifier.issn1308-9234
dc.identifier.issue3
dc.identifier.startpage150
dc.identifier.urihttps://hdl.handle.net/11452/45587
dc.identifier.volume8
dc.identifier.wos000420839800004
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherBilimsel Tıp Yayınevi
dc.relation.journalAstım Allerji Immunoloji
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAsthma
dc.subjectAllergic rhinitis
dc.subjectImmunotherapy
dc.subjectAdverse effects
dc.subjectAllergy
dc.titleIs the subcutaneous allergen immunotherapy safe enough as a treatment modality?
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Göğüs Hastalıkları Ana Bilim Dalı/Alerji Bilim Dalı
local.contributor.departmentTıp Fakültesi/Göğüs Hastalıkları Ana Bilim Dalı
relation.isAuthorOfPublicationea25ddfe-3514-411c-8862-e891b0cd651b
relation.isAuthorOfPublication061153e8-bbd9-4c2a-97f6-dc51171a1143
relation.isAuthorOfPublication.latestForDiscoveryea25ddfe-3514-411c-8862-e891b0cd651b

Files

Collections